SUMMARY To examine the effect of preoperative prostaglandin infusion on surgical mortality the records of all patients aged <28 days operated between January 1979 and December 1981 for obstructive lesions of the systemic circulation were reviewed. Forty patients had coarctation of the aorta, five interrupted aortic arch, and seven critical aortic stenosis. Fourteen patients received intravenous prostaglandin before operation. Among preoperative variables low cardiac output was identified as a possible risk factor for hospital death, whereas the presence of a raised blood urea concentration was possibly significantly associated with hospital mortality only in patients not treated with prostaglandin. The preoperative administration of prostaglandin had a strongly favourable influence: 11 out of 38 (29.0%) patients who did not receive prostaglandin died compared with none of 14 treated with prostaglandin. The two groups were otherwise comparable with respect to the incidence of coagulopathy, urgency of operation, associated anomalies, and other medical treatment. Mean age at operation was younger and mean admission blood urea concentration higher in the group treated with prostaglandin, whereas the incidence of preoperative low cardiac output was probably higher.
Congenital malformations that obstruct the systemic circulation often present with low cardiac output and severe heart failure during the first weeks of life. Closure of the ductus artenosus probably plays an important role in their natural history, and the maintenance of ductal patency by prostaglandin infusion has been reported to improve the clinical condition of some infants with coarctation of the aorta, interrupted aortic arch, and critical aortic stenosis. -4 Although early surgical relief of the obstruction is mandatory, this is associated with a significant mortality. To determine if preoperative prostaglandin infusion might decrease operative mortality, we reviewed our preliminary experience with its use in the management of critically ill infants with obstructive lesions of the systemic circulation.
Requests for reprints to Mr J Stark, FRCS, Thoracic Unit, The Hospital for Sick Children, Great Ormond Street, London WC1N 3JH. Children's Hospital, Liverpool. Accepted for publication 2 August 1984 Patients and methods Between January 1979 (the first year in which prostaglandin was used in our institution for these conditions) and December 1981, 54 patients aged -28 days were identified as having coarctation of the aorta, interrupted aortic arch, or critical aortic stenosis at this hospital. Sixteen of these patients received an intravenous infusion of prostaglandin El. Two were excluded from this study: an 8 day old infant with isolated coarctation died of acute haemorrhage after institution of peritoneal dialysis before operation and a 2 day old infant with mild coarctation died during attempted valvotomy for critical pulmonary stenosis. None of the patients who did not receive prostaglandin died from causes unrelated to left heart obstruction. Patients with hypoplastic left heart syndrome were not treated medically or surgically during this period. The 52 patients in this study ranged in age from 1 to 28 days (mean 10*4 days) at the time of operation. Tables 1 and 2 summarise the anatomical and clinical characterisation of patients who did (group 1) and Prostaglandin and surgery for aortic obstruction infusion. Lower extremity pulses returned to normal volume in three, and one of the eight patients with low cardiac output showed improved peripheral perfusion. The plasma urea concentration fell in five of eight patients in renal failure, and metabolic acidosis decreased in four out of 13. Of the patients showing clinical improvement with prostaglandin infusion, five underwent elective surgery within 48 hours of the onset of infusion, whereas three underwent emergency operation.
Six patients showed no improvement after at least four hours of prostaglandin infusion, and operation was undertaken as an emergency in five of these. In the sixth patient, operation was delayed 24 hours to obtain benefit from peritoneal dialysis.
There were no deaths within seven days of the surgical procedure among the 14 patients treated preoperatively with prostaglandin. By contrast, there were 11 deaths in the first postoperative week in the group of 38 patients who did not receive prostaglandin (29-/0%) (p=0 04). These all occurred at operation or in the immediate postoperative period (Table 3) . Four late deaths (beyond 28 days) occurred in the prostaglandin treated group 1 (28.5%), whereas there were three late deaths among the 27 survivors in the group without prostaglandin (group 2) (11.1%) as summarised in Table 4 . Two of the four patients who died late were among those who had shown preoperative improvement with prostaglandin. Seven day mortality was seven out of 34 (20.6%) among patients who had undergone preoperative cardiac catheterisation, and four out of 18 (22.2%) among those who had not. This difference is not statistically significant. In the group as a whole, no risk factor apart from prostaglandin treatment was statistically significant by logistic regression. In the non-prostaglandin group there was a possible association (logistic p=0 097) between blood urea concentration on admission and death within seven days of operation.
Discussion
Prostaglandin E1 and E2 induce relaxation of ductal tissue in increased as well as low oxygen environments8-I0 and may thereby provide a means of control of ductal patency. In cyanotic congenital heart disease with decreased pulmonary blood flow and ductus dependent pulmonary circulation, prostaglandin affords excellent temporary palliation.' 1-16 More recently, prostaglandin has been used for aortic arch anomalies and coarctation, where part of the systemic circulation may depend on patency of the ductus arteriosus.'-4 17 The aim here is to prevent or alleviate the consequences of ductal closure such as low cardiac output, renal failure, and metabolic acidosis. This study suggests that the benefits of prostaglandin 657 infusion are sufficient in this regard to justify delayed surgical intervention in some patients, thereby significantly reducing operative mortality.
The overall mechanism by which prostaglandin affords haemodynamic improvement in patients with obstructive lesions of the systemic circulation is probably complex and incompletely understood. In neonates with interrupted aortic arch, it has been shown to reduce the pressure gradient between main pulmonary artery and descending aorta, while in those with aortic coarctation it lowers the gradient between the ascending and descending aorta.3 This may reflect relaxation of ductal tissue present inside the aortic lumenl8 or opening of the aortic end of the ductus. 19 In addition, reduction of systemic resistance may benefit patients with isolated simple coarctation, where left ventricular failure has been shown to be related to afterload.20 Venting the right heart and pulmonary circulation towards the lower segment may help to correct fluid overload and acidosis indirectly by increasing renal blood flow.
When the aortic coarctation is associated with a ventricular septal defect, volume overload of the left ventricle, pressure overload of the right ventricle, and pulmonary hypertension occur. Prostaglandin may reduce the left to right shunt at ventricular level in these patients by decreasing systemic afterload, or it may possibly reduce the pressure overload of the right ventricle, again by venting the pulmonary circulation across the ductus. Nevertheless, pulmonary artery pressure does not fall in this condition. 2' In this series, prostaglandin infusion alone resulted in clinical improvement in three patients. When combined with positive inotropic support, there was improvement in an additional five. Six patients, however, showed no changes in their clinical conditions and accordingly underwent emergency operation. In that operative mortality was reduced, even these patients may have had some haemodynamic benefit from the infusion of prostaglandin.
Several factors may have been responsible for a lack of clinical response; in one patient a haematoma of the ductus arteriosus was found at the time of operation and almost certainly caused mechanical occlusion of the ductus. In another 2 week old infant who presented with low cardiac output and severe renal failure, ductal patency may not have been sufficient in itself to reverse established low cardiac output. Prostaglandin had been started at the referring hospital and the ductus was widely patent at operation, although no clinical improvement was observed. The observation that patients with aortic obstruction require a longer period of prostaglandin infusion than infants with cyanotic congenital heart disease to achieve maximal clinical response2' suggests that improved myocardial function may be a prerequisite for clinical improvement in these patients. The most encouraging observation in this study was a significant reduction in operative mortality among the patients who received prostaglandin. Although patients who received prostaglandin were at least as ill preoperatively, as shown by the higher incidence of low cardiac output and renal failure, all survived the operative procedure. These indices of system failure indicate clearly that the younger age of the prostaglandin treated group reflected more serious degrees of cardiac abnormality. It is not possible to argue that the better results in the prostaglandin treated group were due to earlier referral since if this were true they should have had a lower not a higher preoperative incidence of low cardiac output and renal failure.
In both groups of patients late mortality reflected associated cardiac anomalies. As expected, mortality was not affected by prostaglandin and in no case could be attributed to residual aortic obstruction. Based on this limited experience, preoperative infusion of prostaglandin would appear to benefit patients with obstructive lesions of the systemic circulation who have low cardiac output. At present, it is not possible to decide exactly which criteria should be used to assess a patient's response or for how long prostaglandin should be given before operation in either those patients showing improvement or those who fail to respond. Nevertheless, even among patients who showed no detectable clinical improvement the operative mortality was reduced. Accordingly, our present policy is to use prostaglandin infusion in all infants with symptomatic obstructive lesions of the systemic circulation, while hoping that future analysis will clarify the indications particularly in the treatment of critical aortic stenosis. Here the mechanism of any beneficial effect is not as obvious'as in the case of interrupted aortic arch, for example. All that can be said at present is that the results of this study are the same whether patients with critical aortic stenosis are excluded or included and that mortality was lower in those patients with aortic stenosis who were treated with prostaglandin, though the numbers are too small to give statistically significant results.
It is generally believed that preoperative cardiac catheterisation and angiocardiography are essential to the management of this group of patients. If this were so failure to perform cardiac catheterisation in these patients should have constituted a risk factor, whereas the seven day mortality was not significantly different in patients who did and did not undergo preoperative catheterisation. Since preoperative catheterisation itself constitutes a significant risk to these patients22 our results lead us to question the necessity for cardiac catheterisation when all aspects of non-invasive investigation, including clinical assessment, chest radiography, electrocardiography, and cross sectional echocardiography, are typical for the condition suspected. 6 JCH was a British Heart Foundation Overseas fellow, FJM is supported by the Vandervell and British Heart Foundations, and JD is supported by the British Heart Foundation.
